ETF Evaluator:
Amplify Weight Loss Drug & Treatment ETF (THNR)
Follow This ETF
(as of Aug 04)
Best Performing in Health Over the Last Year
| 177.8% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 114.6% | ALPS Medical Breakthroughs ETF (SBIO) |
| 91.7% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 83.9% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 79.5% | iShares Neuroscience and Healthcare ETF (IBRN) |
Risk
Index
Risk
Index
ETF Details
Amplify Weight Loss Drug & Treatment ETF Overview
Amplify Weight Loss Drug & Treatment ETF (THNR) is a passively managed Sector Equity Health exchange-traded fund (ETF). Amplify ETFs launched the ETF in 2024.
The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
About Amplify Weight Loss Drug & Treatment ETF (THNR)
There are 3 members of the management team with an average tenure of 2.04 years: Dustin Lewellyn (2024), Ernesto Tong (2024) and Christine Johanson (2024). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and VettaFi Weight Loss Drug & Treat TR USD index with a weighting of 100%. Amplify Weight Loss Drug & Treatment ETF has 22 securities in its portfolio. The top 10 holdings constitute 60.2% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Amplify Weight Loss Drug & Treatment ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Amplify Weight Loss Drug & Treatment ETF has 40.6% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 56.8% There is 40.6% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Amplify Weight Loss Drug & Treatment ETF has 2.0% of the portfolio in cash.
Assets Under Management
The fund has $4 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
THNR Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Amplify Weight Loss Drug & Treatment ETF expense ratio is average compared to funds in the Health category. Amplify Weight Loss Drug & Treatment ETF has an expense ratio of 0.59%, which is 14% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Amplify Weight Loss Drug & Treatment ETF has a portfolio turnover rate of 70%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 40% for the Health category.
Recently, in the month of June 2026, Amplify Weight Loss Drug & Treatment ETF returned 3.0%, which earned it a grade of F, as the Health category had an average return of 8.7%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Amplify Weight Loss Drug & Treatment ETF has a trailing yield of 1.61%, which is above the 1.12% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Amplify Weight Loss Drug & Treatment ETF Grades
Year to date, the ETF has returned 1.9%, 8.2 percentage points worse than the category, which translates into a grade of F. The fund has returned 15.2% over the past year (grade of D).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Amplify Weight Loss Drug & Treatment ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
THNR Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| THNR Return (NAV) | 3.0% | 5.1% | 15.2% | na | na | na |
| THNR Return (Price) | 3.1% | 4.5% | 15.0% | na | na | na |
| NAV +/- Price Return | -0.074% | 0.616% | 0.199% | na | na | na |
| Health Avg | 8.7% | 13.9% | 37.6% | 10.6% | 1.5% | 9.5% |
| THNR Grade (NAV) | F | F | D | na | na | na |
| +/- Category (NAV) | -5.7% | -8.8% | -22.4% | na | na | na |
| THNR Tax-Cost Ratio | na | na | 0.7% | na | na | na |
THNR Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| THNR Return (NAV) | 1.9% | 13.3% | na | na | na | na | na | na | na | na | na |
| THNR Return (Price) | 1.9% | 13.7% | na | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | -0.033% | 0.030% | na | na | na | na | na | na | na | na | na |
| Health Avg | 10.1% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| THNR Grade (NAV) | F | D | na | na | na | na | na | na | na | na | na |
| +/- Category | -8.2% | -8.5% | na | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | 1.6% |
| Total Assets: | $ 4 Mil |
| Share Class Assets: | $ 4 Mil |
| Turnover: | 70.0% |
| Expense Ratio: | 0.59% |
| Index Fund: | Yes |
| Index Tracked: | S&P 500 (TR) (1970) |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 2.1 years | |||
| Average Tenure: 2.0 years | |||
| Managers (Year): Lewellyn Dustin (2024), Tong Ernesto (2024), Johanson Christine (2024) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 22 |
| % in Top 10 Holdings: | 60.2% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 40.6% |
Portfolio Allocation |
|
| Domestic Stock: | 56.8% |
| Foreign Stock: | 40.6% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.6% |
| Cash: | 2.0% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Amplify ETFs |
| Phone Number: | 855-267-3837 |
| Website: | |
| Inception Date: | May 20, 2024 |
Expenses and Fees
| Expense Ratio (%): | 0.59% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.52% |
